Ashfaq Marghoob, MD, is a dermatologist specializing in the diagnosis and treatment of cancers of the skin and the director of the Memorial Sloan-Kettering regional skin cancer clinic.

Tips on Dermoscopy and Skin Cancer Detection, With Ashfaq Marghoob, MD

, highlighting dermoscopy of special sites and skin cancer detection, with its presenter emphasizing the unique microanatomy of palms, facial skin, soles, and nails.

This workshop was presented by Ashfaq Marghoob, MD, a dermatologist specializing in the diagnosis and treatment of skin cancer and the director of the Memorial Sloan-Kettering regional skin cancer clinic. Marghoob spoke with 

’s editorial team regarding the most important points highlighted in his dermoscopy workshop.

“The first and most important thing was to recognize that special sites in dermoscopy are defined by areas of the skin where the microanatomy differs from the rest of the non-glabrous skin on your body, except the face. So the non-glabrous skin, obviously, is everywhere other than palm soles, mucous membranes, and nails. But on the non-glabrous skin, the face is a special site, because the microanatomy on the face differs, and that is also true for the glabrous areas of the body.”

In his discussion of the dermoscopy workshop, Marghoob described the microanatomy of these areas as different than the rest of the body. The take-home point he highlighted for facial skin was the recognition of facial skin as having an attenuated and rich pattern.

“The next thing that we stressed was that melanoma on the face is derived from the stem cells that reside in the hair bulge, and therefore early melanoma is follicular centric,” Marghoob said. “So there are hyperpigmented follicular openings, irregularity around the follicle, and everything is around the follicle. The extension is from the follicle outward, as opposed to with benign lesions, which will be interfollicular and will be where the changes are, not in the follicle.”

Later in his discussion, Marghoob highlighted palms and soles exhibition of dermatoglyphics, with melanoma pigmentation on ridges and benign lesions in furrows. He further described nail unit dermoscopy highlights, noting clinical features such as nail dystrophy and triangular band shapes, which can overshadow dermoscopic findings.

For any additional information on the topics highlighted in Marghoob’s talk, view the full interview segment posted above.

The quotes used in this video summary were edited for clarity.

Marghoob reported no relevant financial disclosures of note.

Marghoob A. Dermoscopy Workshop: Special Site Dermoscopy. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Ring C, Cox N, Lee JB. Dermatoscopy. Clin Dermatol. 2021 Jul-Aug;39(4):635-642. doi: 10.1016/j.clindermatol.2021.03.009. Epub 2021 Mar 19. PMID: 34809768.


Videos

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Jonggi Choi, MD, PhD, is an associate professor at Asan Medical Center, University of Ulsan College of Medicine, and visiting scholar at Mass General Hospital.

Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD

For many years, concerns about hepatotoxicity have contributed to hesitancy around prescribing statins in patients with chronic liver disease. While recent research has largely addressed and dispelled these concerns, a lack of studies specific to cholestatic conditions like 

A new study from Jonggi Choi, MD, PhD, and colleagues points to a reduced risk of hepatic decompensation and major liver events in patients with PBC taking statins, supporting a potential protective effect in this population.

, Choi addressed longstanding cautions around statins in liver disease head-on, explaining how his team’s findings may help shift the clinical conversation.

Check out part 1 of our discussion with Choi 

“Historically, there has been some concern and hesitancy among physicians prescribing statins in patients with chronic liver disease,” Choi acknowledged, noting that even though multiple studies have demonstrated the general safety of statins in chronic liver disease, apprehension still influences day-to-day prescribing decisions.

His study, which focused largely on stable patients with PBC, most of whom were already receiving ursodeoxycholic acid (UDCA) and had preserved liver function, found no evidence of harm associated with statin use. On the contrary, statins were linked to a significantly lower risk of future liver decompensation.

However, Choi emphasized that the findings should not be interpreted as definitive proof supporting the use of statins specifically for liver protection. Despite the use of a rigorous target trial emulation design to strengthen causal inference, he notes that the data remain observational. Still, he says the study should provide clinicians with reassurance that statins do not need to be withheld in patients with stable PBC or other chronic liver diseases when there is a clear cardiovascular indication.

Looking ahead, Choi outlined several critical next steps. Strengthening causal inference remains a priority, with confirmation ideally coming from randomized controlled trials.

He also highlighted the need for better phenotyping to determine whether statin benefits vary by fibrosis stage, biochemical response to UDCA, or coexisting metabolic risk factors. According to Choi, mechanistic studies are equally important, particularly to clarify how statins’ anti-inflammatory and antifibrotic effects interact with autoimmune cholestatic injury in PBC.

“I see this study as a strong signal-generating step that opens the door for both clinical trials and more refined observational narratives,” Choi said.

Editors’ Note: Choi reports relevant disclosures with Gilead.

Choi J, Xu J, Nguyen VH, et al. Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study. 

Choi explains longstanding hesitancy around statin use in chronic liver disease, particularly cholestatic diseases like PBC, and how his research challenges these sentiments.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Zhiyuan Wu, PhD, is a postdoctoral research fellow at the Harvard T.H. Chan School of Public Health.

Food Quality More Important Than Carbs or Fat for Preventing Heart Disease, With Zhiyuan Wu, PhD

 risk by dieting may depend on the quality of food more than the amount of carbohydrates or fat intake, according to a recent study.

Low-carb and low-fat diets are wildly popular in the US, despite little evidence existing to determine their long-term cardiovascular effects and the role of diet quality within the diet patterns. In this study, investigators aimed to prospectively examine the associations of these diets with coronary heart disease (CHD) risk among US individuals, as well as the objective metabolomic indices associated with the condition.

“Low-carb and low-fat diets are widely practiced in the US for weight control, glucose control, and metabolic health, but their effects on reducing heart disease risk is an ongoing debate, and one with mixed findings,” Zhiyuan Wu, PhD, a postdoctoral research fellow at the Harvard T.H. Chan School of Public Health and lead author of the present study, told 

 in an exclusive interview. “People follow their diets, but they can still choose unhealthy foods.”

Wu and colleagues collected data on 198,473 participants – 42,720 men from the Health Professionals Follow-Up Study (HPFS), 64,164 women in the Nurses’ Health Study (NHS), and 91,589 women from NHSII – to investigate CHD incidence. The team derived 5 low-carb diet and 5 low-fat diet indices based on food frequency questionnaires (FFQs). Each questionnaire emphasized different qualities and sources of macronutrients, including animal- versus plant-based foods, whole grains versus refined carbohydrates, and so on.

The team then assessed multimetabolite scores of low-carb and low-fat diet indices via elastic net regressions among 1146 healthy participants in lifestyle validation studies, which were embedded in NHS, NHSII, and HPFS. Patients were followed up for a total of 5,248,916 person-years, during which 20,033 CHD cases were documented.

Wu and colleagues compared individuals with the highest and lowest low-carb diet scores, determining a pooled multivariable-adjusted hazard ratio for CHD of 1.05 (95% CI, 1.01-1.1) for overall low-carb diets, 1.07 (95% CI, 1.02-1.12) for animal low-carb diets, 0.94 (95% CI, 0.9-0.99) for vegetable low-carb diets, 1.14 (95% CI, 1.09-1.2) for unhealthy low-carb diets, and 0.85 (95% CI, 0.82-0.89) for healthy low-carb diets.

For low-fat diets, the estimated hazard ratios were 0.93 (95% CI, 0.89-0.98) for overall low-fat diets, 0.94 (95% CI, 0.9-0.98) for animal low-fat diets, 0.87 (0.83-0.91) for vegetable low-fat diets, 1.12 (95% CI, 1.07-1.17) for unhealthy low-fat diets, and 0.87 (0.83-0.91) for healthy low-fat diets. The healthy versions of both diet patterns were also linked to lower triglycerides, higher HDL cholesterol, and lower high-sensitivity C-reactive protein levels. Additionally, both diets were associated with favorable metabolomic profiles, including decreased valine and increased 3-indolepropionic acid. Unhealthy patterns displayed opposite associations.

Investigators developed multimetabolite scores for both diet indices in the LVS and replicated in NHS, NHSII, and HPFS (

 = 0.21-0.38). These scores displayed associations with CHD risk, which were highly consistent with those obtained from the FFQ assessments.

Wu and colleagues did, however, note certain limitations of the study. These findings may not be generalizable to more extreme diets, such as ketogenic diets, and should be interpreted within the observed ranges of macronutrients. Additionally, dietary intake was fully self-reported by all patients enrolled in the study and thus was subject to measurement errors. The study findings might also have limited generalizability due to the patient population being health professionals, who presumably had higher health awareness and better access to care.

“For the public, we should still emphasize overall diet patterns rather than strict macronutrient restriction,” Wu said. “I think that focusing on overall diet quality should be an easy program for people to follow, compared with very extreme ways of cutting carbs or fat.”

Editor’s Note: Wu reports no relevant disclosures.

American College of Cardiology. Healthy versions of low-carb and low-fat diets linked to better cardiovascular and metabolic health. 

. February 11, 2026. Accessed February 11, 2026. 

https://www.eurekalert.org/news-releases/1115327

Wu Z, Liu B, Wang X, et al. Effect of low-carbohydrate and low-fat diets on metabolomic indices and coronary heart disease in U.S. individuals. JACC. Published online February 11, 2026. 

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Structural Heart Disease

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

In results from the phase 2 VALIANT trial, verekitug met its primary endpoint of statistically significant reductions in annualized 

 exacerbation rate (AAER) compared with placebo.

The positive topline results were announced by Upstream Bio, Inc, on February 11, 2026, exhibiting clinically meaningful efficacy and a consistent safety profile in adults with severe asthma.

“Severe asthma, when unable to be controlled by standard of care measures, can significantly and chronically disrupt patients’ quality of life, and put them at risk for potentially life-threatening exacerbation events that can lead to emergency room visits and hospitalizations,” said Michael Wechsler, MD, MMSc, a professor of medicine, and director of the National Jewish Cohen Family Asthma Institute, in a statement. “These data suggest that verekitug can potentially offer patients meaningful improvements in their breathing and asthma symptoms with less frequent dosing than the currently available biologics, and I believe that verekitug could represent an important advancement for individuals living with severe asthma.”

As of now, verekitug, a novel, high-affinity, fully human monoclonal antibody, is the only known antagonist targeting the receptor for thymic stromal lymphopoietin in clinical stage development. Besides VALIANT, verekitug is currently in phase 2 development in the VIBRANT study for chronic rhinosinusitis with nasal polyps, and VENTURE for chronic obstructive pulmonary disease.

The phase 2 VALIANT trial was a multicenter, randomized, placebo-controlled parallel group study designed to assess the efficacy and safety of subcutaneously administered verekitug. The study consisted of a 4-week screening period, a 60-week treatment period, and a follow-up period ending 16 weeks after the last dosage.

In the trial, study investigators randomized participants in a 1:1:1:1 ratio to receive 100 mg every 12 weeks (Q12W), 400 mg every 24 weeks (Q24W), 100 mg every 24 weeks (Q24W), or placebo. At each dosing visit, all participants received 2 subcutaneous injections to maintain the blinding of different doses.

VALIANT included a total of 478 patients with severe asthma.

The study’s primary endpoint of a statistically significant and clinically meaningful reduction at AAER was met at Q12W and Q24W dosing. Veretikug demonstrated a 56% reduction of AAER (

< .0003) at 100 mg Q12W and 39% at 400 mg Q24W compared with placebo.

At week 60, the placebo-adjusted improvement in lung function, measured by the forced expiratory volume in one second (FEV1), was 122mL with 100 mg Q12W and 139 mL with 400 mg Q24W. Investigators observed suppressed exhaled nitric oxide (FeNO) by 20.4 ppb (

 <.0001) at 400 mg Q24W. From baseline, these data exhibited a mean reduction of 43.5% (

= .03) in the 100 mg Q12W group and a mean reduction of 44.9% (

= .03) in the 400 mg Q24W group. Additionally, a dosage of 100 mg Q24W demonstrated a statistically significant effect on AAER, but no other endpoints.

At week 24, in prespecified analysis of secondary outcomes, investigators also noted the significant placebo-adjusted improvements compared to baseline in both FEV1 and FeNO with the 100 mg Q12W and 400 mg Q24W dose regimens.

Across all active doses, study investigators reported verekitug was generally well tolerated and demonstrated a favorable safety profile consistent with previous studies.

“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, in a statement. “As we transition into a late clinical-stage company pursuing substantial market opportunities, our focus remains on disciplined execution and expanding Upstream Bio’s capabilities to support long-term growth.”

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma — Wed, 02/11/2026 - 06:00. Upstream Bio. Published 2026. Accessed February 11, 2026. 

https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-reports-positive-top-line-results-phase-2-valiant

Singh D, Brickman CM, Lloyd P, et al. Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial. 

. Published online Winter 2025:10.1002/cpt.70156. doi:

‌Clinicaltrials.gov. Published 2026. Accessed February 11, 2026. 

https://clinicaltrials.gov/study/NCT06196879

Articles

Verekitug, a fully human high-affinity monoclonal antibody antagonizing the thymic stromal lymphopoietin receptor, demonstrated statistically significant and clinically meaningful AAER reductions versus placebo in adults with severe asthma in the phase 2 VALIANT trial. In 478 patients treated for 60 weeks, 100 mg Q12W and 400 mg Q24W reduced AAER by 56% and 39%, respectively, with placebo-adjusted FEV1 gains and FeNO suppression. Safety was generally favorable across doses, supporting rapid progression to phase 3.

Upstream Bio announced positive topline results from the phase 2 VALIANT trial evaluating the efficacy and safety of verekitug in adults with severe asthma.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Jay Lieberman, MD, from University of Tennessee

Brian Schroer, MD, is an allergist-immunologist at the Cleveland Clinic Children's Hospital.

Expanding Epinephrine Options to Reduce Barriers, Improve Early Use

Part 4 of the special report explores one of the most rapidly evolving areas in 

 care: the expanding range of epinephrine delivery options and their potential to overcome long-standing barriers to timely treatment. Panelists reviewed both currently available products and emerging alternatives that may reshape how patients carry and use epinephrine.

The discussion began with a review of injectable options. In the United States, epinephrine autoinjectors are available in 0.1 mg, 0.15 mg, and 0.3 mg doses, while a 0.5 mg autoinjector is available in Europe but not yet in the US. Golden noted that this raises concerns about underdosing in larger adults and underscores the importance of promptly administering a second 0.3 mg dose if symptoms do not improve. Using weight-based dosing (0.01 mg/kg), a 0.3 mg dose is theoretically appropriate for a patient weighing approximately 30 kg (66 pounds), highlighting the need for repeat dosing in adolescents and adults with severe reactions.

Both experts emphasized that syringe-and-needle intramuscular epinephrine remains appropriate in healthcare settings, where dosing can be precisely tailored, even though autoinjectors achieve faster absorption in pharmacokinetic studies. However, many of the persistent gaps in anaphylaxis outcomes stem not from pharmacology but from human factors, including fear of needles, reluctance to carry devices, uncertainty about diagnosis, and hesitation to use epinephrine early.

The panel highlighted the significance of newly approved and emerging non-injectable options. Golden described the first FDA-approved intranasal epinephrine spray (neffy), which has been on the market for over a year.1 Because placebo-controlled anaphylaxis trials are not feasible, approval relied on pharmacokinetic data demonstrating plasma epinephrine levels comparable to existing intramuscular products.2 The nasal spray falls within the therapeutic range between manual intramuscular injection and autoinjectors, and early real-world experience has been encouraging.

The experts discussed additional products in development, including other nasal formulations and a sublingual oral film (Anaphylm) using a prodrug approach to overcome epinephrine’s absorption challenges.3 Lieberman noted that many patients strongly prefer oral medications, making a sublingual option particularly appealing if efficacy is maintained. Newer formulations may also offer practical benefits such as longer shelf life and greater temperature stability.

In closing, Golden and Lieberman returned to the core message of the entire series. Improving anaphylaxis outcomes requires earlier epinephrine use, fewer barriers to administration, and abandoning outdated reliance on antihistamines and corticosteroids in acute care. As Lieberman summarized succinctly: “Epinephrine, epinephrine. Let's stop using steroids for anaphylaxis, and let's use epinephrine early on and get rid of barriers to use.”

, of Cleveland Clinic Children’s Hospital

, of the University of Tennessee Health Science Center

Disclosures include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, BioCryst, GlaxoSmithKline, Amgen, GENZYME Corporation, AstraZeneca Pharmaceuticals, and LEO Pharma for Schroer; Novartis Pharmaceuticals, ABBVIE, Genentech, Aquestive Therapeutics for Lieberman; and Phadia US and Genentech USA for Golden.

Greenhawt M, Schroer B, Kraft C, et al. One Year Later: How Intranasal Epinephrine Is Changing Emergency Allergy Treatment. HCPLive. Published on August 8, 2025. Accessed on February 10, 2026. 

https://join.hcplive.com/view/one-year-later-how-intranasal-epinephrine-is-changing-emergency-allergy-treatment

Smith T. FDA Approves Epinephrine Nasal Spray for Emergency Treatment of Allergic Reactions. HCPLive. Published on August 9, 2024. Accessed on February 10, 2026. 

https://www.hcplive.com/view/fda-approves-epinephrine-nasal-spray-for-emergency-treatment-of-allergic-reactions

Golden D. Anaphylm Remains Promising for Anaphylaxis Despite FDA CRL, With David Golden, MD. HCPLive. Published on February 3, 2026. Accessed on February 10, 2026. 

https://www.hcplive.com/view/anaphylm-remains-promising-anaphylaxis-despite-fda-crl-david-golden-md

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

Special Reports

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.


Recognizing, Managing Anaphylaxis in Infants

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

Delinking Epinephrine Use From Mandatory ED Visits

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

Updated Anaphylaxis Guidelines, Early Management Priorities 

Emily Aman, MPH, from the University of Rochester Medical Center

In an interview with HCPLive, Emily Aman, MPH, and Rachel White, share that most marginalized children with uncontrolled asthma miss specialist visits despite caregiver support due to existing barriers.

Caregiver Perceptions Highlight Gaps in Pediatric Asthma Specialist Access

Adam Bress, PharmD, MS, is a professor of the department of population health sciences at the University of Utah School of Medicine and director of the Integrating Medicine & Policy to Achieve Healthcare Transformation (IMPACT HSR) program.

Bress highlights the potential shortcomings of relying on the Apple Watch as a diagnostic tool for hypertension, discussing its potential for false negatives.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Apple Watch Hypertension Notifications May Give False Reassurance, With Adam Bress, PharmD, MS

Choi describes existing evidence on statin use in patients with liver disease and reviews his new research about their potential utility in PBC.

Statins and Improved Long-Term Liver Outcomes in PBC, With Jonggi Choi, MD, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

FDA News

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Accepts NDA, Grants Priority Review for Oveporexton to Treat Narcolepsy Type 1

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide highlight weight loss of up to 12.1% with no observed plateau at 26 weeks.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Latest News

Tips on Dermoscopy and Skin Cancer Detection, With Ashfaq Marghoob, MD

Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD

Food Quality More Important Than Carbs or Fat for Preventing Heart Disease, With Zhiyuan Wu, PhD

VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial

Expanding Epinephrine Options to Reduce Barriers, Improve Early Use